Advances in pharmacotherapy for tobacco dependence

UMMS Affiliation

Department of Psychiatry



Document Type


Medical Subject Headings

Animals; Blood-Brain Barrier; Clinical Trials as Topic; Combined Modality Therapy; Comorbidity; Drug Administration Routes; Drug Design; Drug Evaluation, Preclinical; Drug Therapy, Combination; Health Education; Humans; Marketing; Mental Disorders; Nicotine; effects; Nicotinic Antagonists; Rats; Smoking; Smoking Cessation; Social Support; Substance Withdrawal Syndrome; Tobacco Use Disorder; Vaccines




The discovery that bupropion is an effective treatment for tobacco dependence has triggered a rapid increase in development of potential new non-nicotine pharmacotherapies, including bromocriptine, glucose, GTS-21, reboxetine, rimonabant, selegeline and varenicline. Successful new products will need to have excellent side-effect profiles in addition to proven efficacy. New faster delivery nicotine replacement products have the promise of addressing a broader list of indications, including treatment of nicotine withdrawal during temporary abstinence and long-term nicotine maintenance. Nicotine vaccines will need to demonstrate efficacy and also improve certain consumer acceptability characteristics (e.g., frequency of injections required) before they can become widely used and successful therapies. The best hope of improved treatment comes from combining existing and new pharmacotherapies with effective behavioural therapy.

Rights and Permissions

Citation: Expert Opin Emerg Drugs. 2004 May;9(1):39-53. Link to article on publisher's site

Related Resources

Link to Article in PubMed

PubMed ID